Skip to content
Axcess News – Lifestyle
Author:
Pharvaris N.V.
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 12, 2026
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
May 8, 2026
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 20, 2026
←
Previous Page
1
2